Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model.

Pieterman, E D; van den Berg, S; van der Meijden, A; Svensson, E M; Bax, H I; de Steenwinkel, J E M

Pieterman, E D; van den Berg, S; van der Meijden, A; Svensson, E M; Bax, H I; de Steenwinkel, J E M.

Afiliação

Pieterman ED; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands.
van den Berg S; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands.
van der Meijden A; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands.
Svensson EM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
Bax HI; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
de Steenwinkel JEM; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, the Netherlands.

Antimicrob Agents Chemother ; 65(4)2021 03 18.

Article em En | MEDLINE | ID: mdl-33558283

Assuntos

Mycobacterium tuberculosis; Rifamicinas; Antituberculosos/farmacologia; Antituberculosos/uso terapêutico; Rifamicinas/farmacologia

Palavras-chave

Mycobacterium tuberculosis; hollow-fiber infection model; pharmacodynamics; pharmacokinetics; rifampin; rifapentine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifamicinas / Mycobacterium tuberculosis Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google